165 related articles for article (PubMed ID: 28109087)
1. CD103
Miao X; Chen Y; Hao K; Zheng M; Chen B; Li K; Wang Y; Zhang W; Zhang Y; Mou X; Jiang S; Wang Z
Oncol Res; 2018 Mar; 26(2):173-182. PubMed ID: 28109087
[TBL] [Abstract][Full Text] [Related]
2. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
3. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
4. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
5. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Salmon H; Idoyaga J; Rahman A; Leboeuf M; Remark R; Jordan S; Casanova-Acebes M; Khudoynazarova M; Agudo J; Tung N; Chakarov S; Rivera C; Hogstad B; Bosenberg M; Hashimoto D; Gnjatic S; Bhardwaj N; Palucka AK; Brown BD; Brody J; Ginhoux F; Merad M
Immunity; 2016 Apr; 44(4):924-38. PubMed ID: 27096321
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
[TBL] [Abstract][Full Text] [Related]
9. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.
Shields BD; Koss B; Taylor EM; Storey AJ; West KL; Byrum SD; Mackintosh SG; Edmondson R; Mahmoud F; Shalin SC; Tackett AJ
Cancer Res; 2019 Mar; 79(6):1113-1123. PubMed ID: 30674537
[TBL] [Abstract][Full Text] [Related]
10. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
11. FLT3/FLT3L-mediated CD103
Zhou CZ; Wang RF; Cheng DL; Zhu YJ; Cao Q; Lv WF
Biomed Pharmacother; 2019 Oct; 118():109031. PubMed ID: 31545219
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
13. Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses.
Jouanneau E; Black KL; Veiga L; Cordner R; Goverdhana S; Zhai Y; Zhang XX; Panwar A; Mardiros A; Wang H; Gragg A; Zandian M; Irvin DK; Wheeler CJ
Cancer Immunol Immunother; 2014 Sep; 63(9):911-24. PubMed ID: 24893855
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
Li JY; Chen YP; Li YQ; Liu N; Ma J
Mol Cancer; 2021 Feb; 20(1):27. PubMed ID: 33541368
[TBL] [Abstract][Full Text] [Related]
16. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of CD103
Williford JM; Ishihara J; Ishihara A; Mansurov A; Hosseinchi P; Marchell TM; Potin L; Swartz MA; Hubbell JA
Sci Adv; 2019 Dec; 5(12):eaay1357. PubMed ID: 31844672
[TBL] [Abstract][Full Text] [Related]
18. CD103
Lu L; Tanaka Y; Ishii N; Sasano T; Sugawara S
Eur J Immunol; 2017 Feb; 47(2):305-313. PubMed ID: 27861804
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
20. Liver-resident CD103+ dendritic cells prime antiviral CD8+ T cells in situ.
Krueger PD; Kim TS; Sung SS; Braciale TJ; Hahn YS
J Immunol; 2015 Apr; 194(7):3213-22. PubMed ID: 25712214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
